(MRX) Marex Ordinary Shares - Overview
Stock: Clearing, Execution, Liquidity, Hedging, Platform
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.60% |
| Yield on Cost 5y | 3.19% |
| Yield CAGR 5y | 110.71% |
| Payout Consistency | 100.0% |
| Payout Ratio | 20.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 36.5% |
| Relative Tail Risk | -12.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.39 |
| Alpha | -1.49 |
| Character TTM | |
|---|---|
| Beta | 1.024 |
| Beta Downside | 1.290 |
| Drawdowns 3y | |
|---|---|
| Max DD | 41.13% |
| CAGR/Max DD | 1.35 |
Description: MRX Marex Ordinary Shares January 11, 2026
Marex Group plc (NASDAQ: MRX) operates a diversified financial-services platform that delivers liquidity, market access, and infrastructure across energy, commodities, and broader financial markets. Its business is split into four segments-Clearing, Agency & Execution, Market Making, and Hedging & Investment Solutions-covering futures and options on metals, agriculture, energy, FX, equities, and fixed income, as well as OTC broking of oil, power, gas, shipping, and freight products. The firm also provides customized OTC derivatives, risk-management tools, structured-note issuance, and proprietary technology platforms such as Neon (trading, risk, data) and Agile (commodity broking).
Key recent metrics (FY 2023) show revenue of approximately $1.1 billion with an operating margin near 12 %, reflecting steady fee-based income despite a volatile commodities backdrop. OTC energy trading volumes grew ~ 15 % YoY, driven by heightened price swings in oil and gas, while the structured-notes franchise expanded ~ 8 % as institutional investors seek diversified yield in a low-interest-rate environment. A macro driver to watch is the ongoing energy price volatility, which can boost trading volumes but also raises margin-compression risk if spreads narrow.
For a deeper, data-driven assessment of MRX’s valuation and risk profile, a quick look at ValueRay’s analyst toolkit can be worthwhile.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 337.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.80 > 1.0 |
| NWC/Revenue: 77.49% < 20% (prev 114.1%; Δ -36.62% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.64b > Net Income 337.5m |
| Net Debt (5.60b) to EBITDA (811.2m): 6.90 < 3 |
| Current Ratio: 1.11 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.7m) vs 12m ago -10.38% < -2% |
| Gross Margin: 42.54% > 18% (prev 0.56%; Δ 4198 % > 0.5%) |
| Asset Turnover: 15.27% > 50% (prev 12.96%; Δ 2.32% > 0%) |
| Interest Coverage Ratio: 1.40 > 6 (EBITDA TTM 811.2m / Interest Expense TTM 558.5m) |
Altman Z'' 0.94
| A: 0.09 (Total Current Assets 32.13b - Total Current Liabilities 29.03b) / Total Assets 32.94b |
| B: 0.03 (Retained Earnings 896.7m / Total Assets 32.94b) |
| C: 0.03 (EBIT TTM 781.3m / Avg Total Assets 26.22b) |
| D: 0.03 (Book Value of Equity 896.7m / Total Liabilities 31.76b) |
| Altman-Z'' Score: 0.94 = BB |
Beneish M -2.92
| DSRI: 0.98 (Receivables 11.04b/7.11b, Revenue 4.01b/2.53b) |
| GMI: 1.33 (GM 42.54% / 56.38%) |
| AQI: 0.08 (AQ_t 0.02 / AQ_t-1 0.28) |
| SGI: 1.58 (Revenue 4.01b / 2.53b) |
| TATA: -0.04 (NI 337.5m - CFO 1.64b) / TA 32.94b) |
| Beneish M-Score: -2.92 (Cap -4..+1) = A |
What is the price of MRX shares?
Over the past week, the price has changed by +2.53%, over one month by +3.79%, over three months by +26.86% and over the past year by +12.54%.
Is MRX a buy, sell or hold?
- StrongBuy: 3
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 50.3 | 24.2% |
| Analysts Target Price | 50.3 | 24.2% |
| ValueRay Target Price | 46.6 | 15.2% |
MRX Fundamental Data Overview February 03, 2026
P/E Forward = 9.3545
P/S = 1.0786
P/B = 2.4011
Revenue TTM = 4.01b USD
EBIT TTM = 781.3m USD
EBITDA TTM = 811.2m USD
Long Term Debt = 2.65b USD (from longTermDebt, last quarter)
Short Term Debt = 6.05b USD (from shortLongTermDebt, last quarter)
Debt = 6.14b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 5.60b USD (from netDebt column, last quarter)
Enterprise Value = 5.91b USD (2.88b + Debt 6.14b - CCE 3.11b)
Interest Coverage Ratio = 1.40 (Ebit TTM 781.3m / Interest Expense TTM 558.5m)
EV/FCF = 3.64x (Enterprise Value 5.91b / FCF TTM 1.62b)
FCF Yield = 27.47% (FCF TTM 1.62b / Enterprise Value 5.91b)
FCF Margin = 40.53% (FCF TTM 1.62b / Revenue TTM 4.01b)
Net Margin = 8.43% (Net Income TTM 337.5m / Revenue TTM 4.01b)
Gross Margin = 42.54% ((Revenue TTM 4.01b - Cost of Revenue TTM 2.30b) / Revenue TTM)
Gross Margin QoQ = 39.74% (prev 38.83%)
Tobins Q-Ratio = 0.18 (Enterprise Value 5.91b / Total Assets 32.94b)
Interest Expense / Debt = 2.37% (Interest Expense 145.4m / Debt 6.14b)
Taxrate = 25.91% (25.6m / 98.8m)
NOPAT = 578.9m (EBIT 781.3m * (1 - 25.91%))
Current Ratio = 1.11 (Total Current Assets 32.13b / Total Current Liabilities 29.03b)
Debt / Equity = 5.21 (Debt 6.14b / totalStockholderEquity, last quarter 1.18b)
Debt / EBITDA = 6.90 (Net Debt 5.60b / EBITDA 811.2m)
Debt / FCF = 3.45 (Net Debt 5.60b / FCF TTM 1.62b)
Total Stockholder Equity = 1.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.29% (Net Income 337.5m / Total Assets 32.94b)
RoE = 31.29% (Net Income TTM 337.5m / Total Stockholder Equity 1.08b)
RoCE = 20.94% (EBIT 781.3m / Capital Employed (Equity 1.08b + L.T.Debt 2.65b))
RoIC = 6.96% (NOPAT 578.9m / Invested Capital 8.31b)
WACC = 4.29% (E(2.88b)/V(9.02b) * Re(9.69%) + D(6.14b)/V(9.02b) * Rd(2.37%) * (1-Tc(0.26)))
Discount Rate = 9.69% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.62%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈1.30b ; Y1≈850.7m ; Y5≈388.2m
Fair Price DCF = 94.40 (EV 12.37b - Net Debt 5.60b = Equity 6.77b / Shares 71.7m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -37.13 | EPS CAGR: -72.26% | SUE: -4.0 | # QB: 0
Revenue Correlation: 37.73 | Revenue CAGR: 6.79% | SUE: 0.00 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.98 | Chg30d=-0.026 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=4.21 | Chg30d=+0.025 | Revisions Net=-1 | Growth EPS=+8.0% | Growth Revenue=+5.6%